News Sentiment

AMPH sentiment intelligence

Amphastar P news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 46 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 18.72 Week of 10 Jul 2026
Weighted tone 46/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-4.7% over one week, -6.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Dimensional Fund Advisors stake in Amphastar Pharmaceuticals (AMPH) hits 5.2%

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -4.7% Price reacting lower
Trend fit Trend inactive -6.8% over four weeks
Fair value -48.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 27
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Market source 7
Stock Titan 6
TradingKey 6
MT Newswires 2
Investing.com 2
Investing.com Canada 1
Seeking Alpha 1

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 14
Analyst action 4
Regulatory and legal 2
Guidance 2
Deals and strategy 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
Stock Titan Direct company coverage

Dimensional Fund Advisors stake in Amphastar Pharmaceuticals (AMPH) hits 5.2%

Dimensional Fund Advisors LP has reported a beneficial ownership of 2,305,107 shares of Amphastar Pharmaceuticals (AMPH) common stock, which represents 5.2% of the class as of June 30, 2026. The firm exercises sole voting power over 2,251,660 shares and sole dispositive power ove

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 Jul 2026 17:12
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Amphastar P For: 13 July By Investing.com

The article is a brief financial post from Investing.com, likely announcing a Form 4 filing for Amphastar Pharmaceuticals on July 13th. The content primarily consists of navigation links, advertisements, and market data, with very little substantive information about the Form 4 i

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 00:09
Source
Investing.com Canada
Stock Titan Direct company coverage

Amphastar Pharmaceuticals (AMPH) director reports initial insider ownership

Amphastar Pharmaceuticals director Anthony T. Pierce has filed an initial insider ownership report (Form 3), indicating his status as a director but showing no equity or derivative holdings as of the report date. The filing reports zero buy, sell, or other transactions in Amphast

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

Amphastar (AMPH) director awarded 7,886 RSUs and 16,646 options at $19.02

Amphastar Pharmaceuticals director Anthony T. Pierce was granted 7,886 restricted stock units (RSUs) and 16,646 stock options on July 9, 2026, as equity compensation. Both the RSUs and options will vest on July 9, 2027, with the options exercisable at $19.02 per share and expirin

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

[8-K] Amphastar Pharmaceuticals, Inc. Reports Material Event

Amphastar Pharmaceuticals, Inc. announced an increase in its Board of Directors from ten to eleven members and appointed Anthony Pierce as a Class III director, effective July 9, 2026. Mr. Pierce will serve until the 2028 annual meeting and has been deemed independent by Nasdaq s

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 09:41
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – DUS:29A

This article provides financial information for Amphastar Pharmaceuticals, Inc. (DUS:29A) on TradingView, focusing specifically on its enterprise value to EBITDA forward ratio. It indicates that the market was closed with no trades recorded at the time of publication. The content

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 00:39
Source
TradingView
Seeking Alpha Direct company coverage

Amphastar stock slips on FDA warning letter (AMPH:NASDAQ)

Amphastar Pharmaceuticals (AMPH) saw its stock decline after one of its subsidiaries, International Medication Systems, Limited, received a warning letter from the U.S. FDA. The warning letter cited manufacturing-related violations at a facility in California. This news led to a

Tone
Negative 28/100
Event
Market update
Published
08 Jul 2026 11:39
Source
Seeking Alpha
Stock Titan Direct company coverage

FDA Warning Letter targets Amphastar (NASDAQ: AMPH) IMS manufacturing facility

Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that its subsidiary, International Medication Systems (IMS), received an FDA Warning Letter on July 2, 2026, for its South El Monte, California manufacturing facility. The letter cites violations of Good Manufacturing Practice re

Tone
Negative 28/100
Event
Market update
Published
08 Jul 2026 10:11
Source
Stock Titan
TradingView Direct company coverage

Amphastar Pharmaceuticals subsidiary receives FDA warning letter over CGMP issues at California facility

Amphastar Pharmaceuticals received an FDA Warning Letter for CGMP violations at its IMS South El Monte manufacturing facility on July 2, 2026, following a December 2025 inspection. The violations relate to investigation procedures, environmental monitoring, handling, and manufact

Tone
Negative 18/100
Event
Regulatory and legal
Published
08 Jul 2026 10:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH

The article focuses on the "Price to earnings forward" metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) as displayed on TradingView. It provides a snapshot of this financial data point, indicating that the market is currently closed with no trades. The majority of the co

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 14:12
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Amphastar Pharmaceuticals, Inc. – DUS:29A

This article provides financial information for Amphastar Pharmaceuticals, Inc. (DUS:29A) on the Dusseldorf Stock Exchange. It specifically highlights the company's price to earnings forward metric. The content largely consists of navigation and technical information related to T

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 01:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH

This article focuses on the enterprise value to revenue forward metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It appears to be a financial data snippet from TradingView, providing an overview of this specific financial ratio for the company. The content primarily dis

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 08:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH

This article identifies the enterprise value to EBIT forward for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It is a finance-related piece from TradingView, which also provides additional market and financial data for the company. The article itself is a placeholder or title

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

Amphastar Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $22, Implies 1% Upside

Amphastar Pharmaceuticals, Inc. (AMPH) has seen its average 12-month price target cut from $22.83 to $22 by analysts, with a range of $19 to $30 per share. This new target implies a modest 1% potential upside from its June 26 closing price. The consensus rating among seven analys

Tone
Negative 38/100
Event
Analyst action
Published
29 Jun 2026 13:41
Source
TradingView
www.marketscreener.com Direct company coverage

Amphastar Pharmaceuticals, Inc.(NasdaqGS: AMPH) added to Russell 2000 Dynamic Index

Amphastar Pharmaceuticals, Inc. (NasdaqGS: AMPH) has been added to the Russell 2000 Dynamic Index, effective June 28, 2026. This news comes shortly after the company was dropped from several other Russell Growth benchmarks. The biopharmaceutical company focuses on developing and

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 08:41
Source
www.marketscreener.com
TradingView Direct company coverage

Price to sales forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH

This article provides a brief snapshot of the "Price to sales forward" metric for Amphastar Pharmaceuticals, Inc. (AMPH) on the Nasdaq Stock Market. It indicates the stock market is closed with no trades. The main content focuses on navigation and related financial data services

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 08:38
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. – LS:A11664

This article focuses on the enterprise value to revenue forward metric for Amphastar Pharmaceuticals, Inc. (LS:A11664) as presented on TradingView. It appears to be a stub or data-focused page without detailed analysis, indicating that this financial metric is being tracked for t

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 03:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Amphastar Pharmaceuticals, Inc. – LS:A11664

This article displays the "Price to earnings forward" metric for Amphastar Pharmaceuticals, Inc. (LS:A11664) from TradingView. The content indicates that the market is closed and no trades have occurred for this specific data point. It is presented within the context of financial

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

AMPH Forecast — Price Target — Prediction for 2027

This article provides a forecast for Amphastar Pharmaceuticals, Inc. (AMPH) stock, including analyst price targets, historical performance data, and financial metrics. It also addresses frequently asked questions about the company's stock, such as earnings reports, revenue, net i

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 19:41
Source
TradingView
TradingView Direct company coverage

Amphastar Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMPH)

This article provides an overview of Amphastar Pharmaceuticals, Inc. (AMPH) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price estimates, recent financial results, and future earnings

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 01:10
Source
TradingView
TradingKey Direct company coverage

Amphastar Pharmaceuticals Inc (AMPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Amphastar Pharmaceuticals Inc (AMPH), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis indicates that AMPH's current price momentum score is 6.46, placin

Tone
Negative 39/100
Event
Market update
Published
22 Jun 2026 16:41
Source
TradingKey
Intellectia AI Direct company coverage

AMPH Technical Analysis & Stock Price Forecast

This article provides a technical analysis and stock price forecast for Amphastar Pharmaceuticals, Inc (AMPH), indicating a "Strong Sell" consensus based on various technical indicators and moving averages. The analysis highlights that AMPH's share price is currently $18.81, trad

Tone
Negative 27/100
Event
Guidance
Published
19 Jun 2026 04:10
Source
Intellectia AI
TradingKey Direct company coverage

Amphastar Pharmaceuticals Inc (AMPH) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Amphastar Pharmaceuticals Inc (AMPH)'s financial health, noting its stable financial status and high operating efficiency, with a current financial score of 8.76. The company's latest quarterly revenue increased by 0.38% year-over-year, and it

Tone
Positive 70/100
Event
Earnings
Published
19 Jun 2026 03:40
Source
TradingKey
TradingKey Direct company coverage

Amphastar Pharmaceuticals Inc (AMPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Amphastar Pharmaceuticals Inc (AMPH) by business segment and geographical region. It highlights that "Other products" and "BAQSIMI" are the largest revenue contributors, while the United States accounts for the vast majority

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 13:12
Source
TradingKey
TradingKey Direct company coverage

Amphastar Pharmaceuticals Inc (AMPH) Institutional Confidence

Amphastar Pharmaceuticals Inc (AMPH) has an institutional shareholding score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The current institutional shareholding proportion is 79.72%, which is a 6.44% decrease quarter-over-quarter. James Simons is the large

Tone
Negative 40/100
Event
Market update
Published
18 Jun 2026 03:12
Source
TradingKey
TradingKey Direct company coverage

Amphastar Pharmaceuticals Inc (AMPH) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Amphastar Pharmaceuticals Inc (AMPH) focusing on its dividend and stock split history. It notes that no dividends have been distributed by the company over the past five years and no stock split data is available. The page also presents curren

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 20:39
Source
TradingKey
TradingKey Direct company coverage

Amphastar Pharmaceuticals Inc (AMPH) Earnings Forecast: Future EPS & Revenue Growth Estimates

Amphastar Pharmaceuticals Inc (AMPH) has an earnings forecast score of 6.00, ranking 132nd in the Pharmaceuticals industry. Analysts have set an average price target of $31.00 for AMPH, with a "Hold" rating based on 7 analysts. The company's expected revenue for the next quarter

Tone
Positive 62/100
Event
Earnings
Published
17 Jun 2026 02:39
Source
TradingKey